4,954 United Therapeutics Corporation $UTHR Shares Acquired by University of Texas Texas AM Investment Management Co.

University of Texas Texas AM Investment Management Co. lifted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 53.1% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 14,282 shares of the biotechnology company’s stock after acquiring an additional 4,954 shares during the period. United Therapeutics makes up approximately 1.0% of University of Texas Texas AM Investment Management Co.’s investment portfolio, making the stock its 22nd largest holding. University of Texas Texas AM Investment Management Co.’s holdings in United Therapeutics were worth $7,739,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of UTHR. Toth Financial Advisory Corp raised its position in shares of United Therapeutics by 2,400.0% in the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 48 shares during the last quarter. Fiduciary Financial Advisors acquired a new stake in United Therapeutics in the 2nd quarter worth approximately $30,000. Caitlin John LLC acquired a new stake in United Therapeutics in the 2nd quarter worth approximately $37,000. International Assets Investment Management LLC grew its position in United Therapeutics by 426.7% during the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 64 shares during the last quarter. Finally, PFS Partners LLC purchased a new stake in United Therapeutics during the 3rd quarter worth approximately $45,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. TD Cowen upped their price target on shares of United Therapeutics from $675.00 to $700.00 and gave the company a “buy” rating in a research note on Thursday. Leerink Partners raised their price target on shares of United Therapeutics from $685.00 to $725.00 and gave the stock an “outperform” rating in a report on Monday, October 19th. JPMorgan Chase & Co. lowered their price objective on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating for the company in a research note on Wednesday, October 28th. Jefferies Financial Group reissued a “buy” rating and set a $728.00 price objective on shares of United Therapeutics in a report on Wednesday, October 14th. Finally, Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Thirteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $676.40.

Insiders Place Their Bets

In other United Therapeutics news, CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $526.96, for a total transaction of $5,006,120.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $170,968,483.28. This trade represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 401,528 shares of company stock valued at $213,440,124. 8.60% of the stock is currently owned by corporate insiders.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analysts raised their price targets and kept bullish ratings. BTIG maintained a Buy rating with a $768 target, citing Tyvaso momentum; Royal Bank of Canada raised its target to $725 and TD Cowen to $700. BTIG analyst outlook
• Positive Sentiment: Third-quarter revenue increased 4.1% year over year to $832.5 million, exceeding analyst expectations of about $781 million. The company also has a $2 billion share-repurchase authorization, which could support demand for its shares.
• Negative Sentiment: Quarterly EPS of $5.71 missed the $6.01 consensus and was below $7.16 a year earlier. The earnings shortfall and year-over-year decline in EPS could offset the revenue beat.
• Negative Sentiment: CEO Martine Rothblatt reported multiple share sales, while EVP Paul Mahon sold 8,300 shares. Insider sales can unsettle investors, although both executives retained substantial holdings after their transactions. CEO sale filing EVP sale filing

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $562.02 on Monday. United Therapeutics Corporation has a 52-week low of $444.04 and a 52-week high of $614.23. The stock has a market cap of $23.94 billion, a price-to-earnings ratio of 21.21, a PEG ratio of 3.78 and a beta of 0.49. The business has a 50-day moving average price of $533.99 and a 200-day moving average price of $533.42.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). The firm had revenue of $832.50 million for the quarter, compared to analyst estimates of $781.14 million. United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period last year, the firm earned $7.16 EPS. As a group, equities analysts anticipate that United Therapeutics Corporation will post 24.77 EPS for the current fiscal year.

United Therapeutics announced that its board has authorized a share buyback program on Thursday, October 22nd that allows the company to buy back $2 billion in outstanding shares. This repurchase authorization allows the biotechnology company to repurchase up to 8.3% of its shares through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its shares are undervalued.

About United Therapeutics

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma.

Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.